Compare FORM & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | PTCT |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | 2002 | 2006 |
| Metric | FORM | PTCT |
|---|---|---|
| Price | $127.85 | $71.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | ★ $91.63 | $80.65 |
| AVG Volume (30 Days) | ★ 1.5M | 775.1K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 0.69 | ★ 7.78 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $7.31 | $19.02 |
| P/E Ratio | $188.04 | ★ $9.45 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $23.79 | $35.95 |
| 52 Week High | $136.00 | $87.50 |
| Indicator | FORM | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.29 | 58.12 |
| Support Level | $90.63 | $69.81 |
| Resistance Level | N/A | $79.59 |
| Average True Range (ATR) | 6.75 | 2.21 |
| MACD | 2.38 | 0.63 |
| Stochastic Oscillator | 81.90 | 80.79 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.